Azithromycin Dosage for Mycobacterium fortuitum Treatment

Critical Resistance Consideration

All M. fortuitum isolates contain an inducible erythromycin methylase erm(39) gene that confers resistance to macrolides, making them unreliable as monotherapy despite 80% showing "susceptible" minimum inhibitory concentrations (MICs) for clarithromycin, according to the American Thoracic Society 1
This inducible resistance mechanism means that macrolides should be used with significant caution in M. fortuitum infections, even when in vitro testing suggests susceptibility, as recommended by the American College of Chest Physicians 1

For pulmonary M. fortuitum disease, the American Thoracic Society recommends using at least two agents with in vitro activity for a minimum of 12 months after sputum culture conversion 1
If azithromycin is included, typical dosing is 250-500 mg once daily, as suggested by the British Thoracic Society 2
Combination options based on susceptibility testing typically include: fluoroquinolones (ciprofloxacin/ofloxacin), sulfonamides, doxycycline/minocycline, or amikacin, according to the Infectious Diseases Society of America 1

M. fortuitum is typically susceptible to multiple oral agents that may be superior choices to macrolides, including fluoroquinolones, sulfonamides, amikacin, imipenem, doxycycline, and cefoxitin, as reported by the American Thoracic Society 1

Drug susceptibility testing is mandatory for M. fortuitum to guide effective therapy, as emphasized by the American College of Chest Physicians 1
Surgery is generally indicated with extensive disease, abscess formation, or when drug therapy proves difficult, according to the Society of Thoracic Surgeons 1
Foreign body removal (e.g. implanted devices) is essential for recovery, as recommended by the Infectious Diseases Society of America 1